Caribou Biosciences, Inc. (CRBU)
| Market Cap | 210.27M +173.6% |
| Revenue (ttm) | 11.20M +13.0% |
| Net Income | -133.22M |
| EPS | -1.41 |
| Shares Out | 98.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,446,874 |
| Open | 2.130 |
| Previous Close | 2.120 |
| Day's Range | 1.990 - 2.320 |
| 52-Week Range | 0.769 - 3.535 |
| Beta | 2.27 |
| Analysts | Strong Buy |
| Price Target | 11.25 (+425.7%) |
| Earnings Date | May 7, 2026 |
About CRBU
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCM... [Read more]
Financial Performance
In 2025, Caribou Biosciences's revenue was $11.16 million, an increase of 11.66% compared to the previous year's $9.99 million. Losses were -$148.13 million, -0.66% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price target is $11.25, which is an increase of 425.70% from the latest price.
News
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou's ma...
Caribou Biosciences Transcript: Bank of America Global Healthcare Conference 2026
Two off-the-shelf CAR-T therapies are advancing, with vispa-cel showing durable, auto CAR T-like responses in lymphoma and CB-011 exceeding bispecific benchmarks in multiple myeloma. Phase III for vispa-cel targets patients ineligible for auto CAR T, with broad commercial and manufacturing scalability. Key data updates are expected at EHA and year-end.
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts hav...
Caribou Biosciences price target raised to $11 from $9 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Caribou Biosciences (CRBU) to $11 from $9 and keeps a Buy rating on the shares post the Q1 report.
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- -- CaMMoufl...
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, ...
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve ...
Caribou Biosciences Transcript: Leerink Global Healthcare Conference 2026
Key clinical updates include pivotal trial planning for vispa-cel and expansion of CB-011, with robust FDA engagement and a focus on scalable, low-cost manufacturing. Financing will blend equity and partnerships, while commercialization will be direct in the U.S. and partner-driven globally.
Caribou Biosciences price target raised to $13 from $11 at Evercore ISI
Evercore ISI raised the firm’s price target on Caribou Biosciences (CRBU) to $13 from $11 and keeps an Outperform rating on the shares. While CD19 and BCMA data look “promising,”…
Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year
Reports Q4 revenue $3.94M vs. $2.08M last year. “2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel…
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial result...
Caribou Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit
The summit highlighted advances in allogeneic CAR-T therapies, with pivotal-ready programs for lymphoma and myeloma showing strong efficacy and safety. Upcoming pivotal trials target large unmet needs, with broad access strategies and commercial launches planned.
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample
BOULDER, Colo.--(BUSINESS WIRE)-- #NGS--Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosc...
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will ...
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data d...
Caribou Biosciences initiated with a Buy at Clear Street
Clear Street initiated coverage of Caribou Biosciences (CRBU) with a Buy rating and $13 price target Caribou is developing a pipeline of off-the-shelf allogeneic CAR-T cell therapies, including lead a...
Caribou Biosciences price target lowered to $6 from $8 at BofA
BofA lowered the firm’s price target on Caribou Biosciences (CRBU) to $6 from $8 and keeps a Buy rating on the shares. The firm is updating its price targets for…
Caribou Biosciences Transcript: The 67th American Society of Hematology (ASH) Annual Meeting
Vispa-cel, an off-the-shelf CAR T-cell therapy, demonstrates efficacy and safety comparable to autologous CAR T, with the potential to address major access barriers for large B-cell lymphoma patients. Community and academic experts anticipate a paradigm shift if approved, expanding curative options to underserved populations.
Caribou Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference
Vispa-cel shows auto CAR-T-like efficacy and safety in dual ineligible lymphoma patients, with scalable manufacturing and rapid availability. Regulatory and market access strategies target broad adoption in community centers, while CB-011 in myeloma aims to match bispecifics and expand patient access.
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hos...
Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year
Reports Q3 revenue $2.2M vs. $2.0M last year. Cash, cash equivalents, and marketable securities were $159.2M as of September 30. Caribou expects its cash runway will be sufficient to fund…
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class...
Caribou Biosciences price target raised to $9 from $3 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Caribou Biosciences (CRBU) to $9 from $3 and keeps a Buy rating on the shares. The firm cites the new data for…
Caribou Biosciences price target raised to $8 from $5 at Citi
Citi raised the firm’s price target on Caribou Biosciences (CRBU) to $8 from $5 and keeps a Buy rating on the shares, citing “meaningfully increased conviction” in the allogenic CAR-T…
Caribou Biosciences Transcript: Study Result
Phase I data show vispa-cel and CB-011, both allogeneic CAR-T therapies, deliver efficacy and safety on par with autologous CAR-T, with rapid, scalable manufacturing and potential to greatly expand patient access in lymphoma and myeloma.